Antibodies against Immature Virions Are Not a Discriminating Factor for Dengue Disease Severity

PLoS Neglected Tropical Diseases

Volumn 9, Issue 3, 2015, Pages

  Rodenhuis Zybert, Izabela A ^a   da Silva Voorham, Júlia M ^a   Torres, Silvia ^a   van de Pol, Denise ^a   Smit, Jolanda M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BICARBONATE; GLYCOPROTEIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEMBRANE PROTEIN; MEMBRANE PROTEIN M; PENICILLIN DERIVATIVE; PRM PROTEIN; STREPTOMYCIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

AEDES ALBOPICTUS; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENGUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMATURE VIRUS; NONHUMAN; PROTEIN CLEAVAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRION; VIROGENESIS; VIRUS INFECTIVITY; WESTERN BLOTTING; BLOOD; DENGUE VIRUS; IMMUNOLOGY;

ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; VIRAL ENVELOPE PROTEINS; VIRION;

EID: 84928819520     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003564     Document Type: Article

References (60)

1. Mackenzie JS, Gubler DJ, Petersen LR, Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10:S98–109. 15577938
2. WHO. Dengue: guidelines for diagnosis, treatment, prevention and control—New edition. Geneve, 2009.
3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504–7. Epub 2013 Apr 7. doi: 10.1038/nature12060 23563266
4. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 1997.
5. Rodenhuis-Zybert IA, Wilschut J, Smit JM, Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci; 67:2773–86. doi: 10.1007/s00018-010-0357-z 20372965
6. Halstead SB, O'Rourke EJ, Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977; 146:201–17. 406347
7. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS, Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444–51. 2712199
8. Burke DS, Kliks S, Antibody-dependent enhancement in dengue virus infections. J Infect Dis 2006; 193:601–3; author reply 3–4. 16425142
9. Halstead SB, In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140:527–33. 117061
10. Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010; 6:e1000790. doi: 10.1371/journal.ppat.1000790 20168989
11. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2–9. 10608744
12. Morens DM, Venkateshan CN, Halstead SB, Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J Gen Virol 1987; 68 (Pt 1):91–8. 2433388
13. Halstead SB, Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476–81. 3277268
14. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC, The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995; 375:291–8. 7753193
15. Modis Y, Ogata S, Clements D, Harrison SC, A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 2003; 100:6986–91. 12759475
16. Zhang Y, Zhang W, Ogata S, et al. Conformational changes of the flavivirus E glycoprotein. Structure 2004; 12:1607–18. 15341726
17. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH, Crystal structure of the West Nile virus envelope glycoprotein. J Virol 2006; 80:11467–74. 16987985
18. Li L, Lok SM, Yu IM, et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008; 319:1830–4. doi: 10.1126/science.1153263 18369147
19. Zybert IA, van der Ende-Metselaar H, Wilschut J, Smit JM, Functional importance of dengue virus maturation: infectious properties of immature virions. J Gen Virol 2008; 89:3047–51. doi: 10.1099/vir.0.2008/002535-0 19008392
20. Junjhon J, Lausumpao M, Supasa S, et al. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction. J Virol 2008; 82:10776–91. doi: 10.1128/JVI.01180-08 18715923
21. Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008; 82:6631–43. doi: 10.1128/JVI.00316-08 18448542
22. Beltramello M, Williams KL, Simmons CP, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271–83. doi: 10.1016/j.chom.2010.08.007 20833378
23. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745–8. doi: 10.1126/science.1185181 20448183
24. Lai CY, Williams KL, Wu YC, et al. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 2013; 7:e2451. eCollection 2013. doi: 10.1371/journal.pntd.0002451 24069496
25. Crill WD, Hughes HR, Delorey MJ, Chang GJ, Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 2009; 4:e4991. doi: 10.1371/journal.pone.0004991 19337372
26. de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 2012; 109:7439–44. Epub 2012 Apr 12. doi: 10.1073/pnas.1200566109 22499787
27. Teoh EP, Kukkaro P, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 2012; 4:139ra83. doi: 10.1126/scitranslmed.3003888 22723463
28. Messer WB, de Alwis R, Yount BL, et al. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A 2014; 111:1939–44. Epub 2014 Jan 2. doi: 10.1073/pnas.1317350111 24385585
29. de Alwis R, Beltramello M, Messer WB, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 2011; 5:e1188. doi: 10.1371/journal.pntd.0001188 21713020
30. Valdes K, Alvarez M, Pupo M, Vazquez S, Rodriguez R, Guzman MG, Human Dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol 2000; 7:856–7. 10973471
31. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, et al. Immature dengue virus: a veiled pathogen? PLoS Pathog 2010; 6:e1000718. doi: 10.1371/journal.ppat.1000718 20062797
32. Rodenhuis-Zybert IA, Moesker B, da Silva Voorham JM, et al. A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J Virol 2011; 85:11800–8. Epub 2011 Aug 31. doi: 10.1128/JVI.05237-11 21880758
33. da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nunez NV, et al. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One 2012; 7:e29957. Epub 2012 Mar 14. doi: 10.1371/journal.pone.0029957 22431958
34. Chan AH, Tan HC, Chow AY, et al. A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein. PLoS One 2012; 7:e33451. Epub 2012 Apr 3. doi: 10.1371/journal.pone.0033451 22509258
35. Zhang X, Fugere M, Day R, Kielian M, Furin processing and proteolytic activation of Semliki Forest virus. J Virol 2003; 77:2981–9. 12584323
36. Zheng A, Umashankar M, Kielian M, In vitro and in vivo studies identify important features of dengue virus pr-E protein interactions. PLoS Pathog 2010; 6:e1001157. doi: 10.1371/journal.ppat.1001157 20975939
37. Narvaez F, Gutierrez G, Perez MA, et al. Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS Negl Trop Dis 2011; 5:e1397. Epub 2011 Nov 8. doi: 10.1371/journal.pntd.0001397 22087348
38. Fernandez RJ, Vazquez S, Serological diagnosis of dengue by an ELISA inhibition method (EIM). Mem Inst Oswaldo Cruz 1990; 85:347–51. 2134709
39. Balmaseda A, Hammond SN, Tellez Y, et al. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Trop Med Int Health 2006; 11:935–42. 16772016
40. Balmaseda A, Hammond SN, Perez L, et al. Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg 2006; 74:449–56. 16525106
41. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV, Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol 1992; 30:545–51. 1372617
42. Harris E, Roberts TG, Smith L, et al. Typing of dengue viruses in clinical specimens and mosquitoes by single-tube multiplex reverse transcriptase PCR. J Clin Microbiol 1998; 36:2634–9. 9705406
43. Nogueira RM, Miagostovich MP, Lampe E, Souza RW, Zagne SM, Schatzmayr HG, Dengue epidemic in the state of Rio de Janeiro, Brazil, 1990–1: co-circulation of dengue 1 and dengue 2 serotypes. Epidemiol Infect 1993; 111:163–70. 8348928
44. Harris E, Videa E, Perez L, et al. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 2000; 63:5–11. 11357995
45. van der Schaar HM, Rust MJ, Waarts BL, et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 2007; 81:12019–28. 17728239
46. de Souza VA, Tateno AF, Oliveira RR, et al. Sensitivity and specificity of three ELISA-based assays for discriminating primary from secondary acute dengue virus infection. J Clin Virol 2007; 39:230–3. Epub 2007 May 16. 17509934
47. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E, Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol 2000; 74:7814–23. 10933688
48. Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E, Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis 2013; 7:e2274. Print 2013. doi: 10.1371/journal.pntd.0002274 23785536
49. Roehrig JT, Bolin RA, Kelly RG, Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998; 246:317–28. 9657950
50. Sung SS, Phagocytosis by mouse peritoneal macrophages plated on monoclonal antibody-coated immune complex-substrates: effects of complexes of different IgG subclasses on Fc receptor functions. J Immunol 1985; 135:1981–6. 4020136
51. Ochiai H, Kurokawa M, Hayashi K, Niwayama S, Antibody-mediated growth of influenza A NWS virus in macrophagelike cell line P388D1. J Virol 1988; 62:20–6. 3334744
52. Nelson S, Jost CA, Xu Q, et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 2008; 4:e1000060. doi: 10.1371/journal.ppat.1000060 18464894
53. Cherrier MV, Kaufmann B, Nybakken GE, et al. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. Embo J 2009; 28:3269–76. doi: 10.1038/emboj.2009.245 19713934
54. Rodenhuis-Zybert IA, Wilschut J, Smit JM, Partial maturation: an immune-evasion strategy of dengue virus? Trends Microbiol 2011; 19:248–54. doi: 10.1016/j.tim.2011.02.002 21388812
55. Pierson TC, Diamond MS, Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol 2012; 2:168–75. Epub Mar 23. doi: 10.1016/j.coviro.2012.02.011 22445964
56. Huang KJ, Yang YC, Lin YS, et al. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 2006; 176:2825–32. 16493039
57. Buddhari D, Aldstadt J, Endy TP, et al. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis 2014; 8:e3230. eCollection 2014 Oct. doi: 10.1371/journal.pntd.0003230 25329173
58. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 10:61428–7.
59. Halstead SB, Dengue. Lancet 2007; 370:1644–52. 17993365
60. Martina BE, Koraka P, Osterhaus AD, Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 2009; 22:564–81. doi: 10.1128/CMR.00035-09 19822889